1. Home
  2. CMPS vs DCTH Comparison

CMPS vs DCTH Comparison

Compare CMPS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$6.78

Market Cap

598.7M

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.44

Market Cap

289.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPS
DCTH
Founded
2020
1988
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
598.7M
289.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CMPS
DCTH
Price
$6.78
$10.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$16.43
$22.60
AVG Volume (30 Days)
1.6M
739.3K
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$79,603,000.00
Revenue This Year
N/A
$131.97
Revenue Next Year
N/A
$38.84
P/E Ratio
N/A
$300.67
Revenue Growth
N/A
251.54
52 Week Low
$2.25
$8.12
52 Week High
$7.13
$18.23

Technical Indicators

Market Signals
Indicator
CMPS
DCTH
Relative Strength Index (RSI) 66.43 62.85
Support Level $4.90 $9.59
Resistance Level $5.57 $10.14
Average True Range (ATR) 0.38 0.44
MACD 0.20 0.16
Stochastic Oscillator 84.53 87.15

Price Performance

Historical Comparison
CMPS
DCTH

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: